Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. [electronic resource]
Producer: 20051101Description: 6247-55 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Cytarabine -- administration & dosage
- Drug Administration Schedule
- Drug Carriers
- Drug Combinations
- Female
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Polyethylene Glycols -- administration & dosage
- Recombinant Proteins
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.